Aurinia Pharmaceuticals, the US-listed biotechnology company developing treatments for rare diseases, is rumoured to be "close to picking" a preferred bidder as its strategic review draws to a close.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
